๐Ÿ“–
Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update.
Jiang J, Wojtowicz A, Uyei J, Jin H, Lindsley K, Sanchirico M

Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in BMC Gastroenterol.

Advertisement
SPONSOR CONTENT
Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update.
Author / Organization Jiang J, Wojtowicz A, Uyei J, Jin H, Lindsley K, Sanchirico M
Subject & Discipline BMC Gastroenterol
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-62960
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »